Cargando…
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder
BACKGROUND: Asverin® (tipepidine hibenzate) has been used as an antitussive for > 50 years in Japan. Studies revealed that tipepidine modulates monoamine levels, by inhibiting G-protein-activated inwardly rectifying potassium (GIRK) channels, expecting the potential therapeutic effects of tipepid...
Autores principales: | Saito, Takuya, Yamashita, Yushiro, Tomoda, Akemi, Okada, Takashi, Umeuchi, Hideo, Iwamori, Saki, Shinoda, Satoru, Mizuno-Yasuhira, Akiko, Urano, Hidetoshi, Nishino, Izumi, Saito, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653993/ https://www.ncbi.nlm.nih.gov/pubmed/33167920 http://dx.doi.org/10.1186/s12888-020-02932-2 |
Ejemplares similares
-
A pediatric case of anaphylactic shock induced by tipepidine hibenzate (Asverin)
por: Takai, Hirotake, et al.
Publicado: (2018) -
Anaphylaxis caused by tipepidine hibenzate, a central antitussive drug
por: Mochizuki, Eisuke, et al.
Publicado: (2015) -
Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials
por: Inoue, Yuichi, et al.
Publicado: (2022) -
Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study
por: Sasaki, Tsuyoshi, et al.
Publicado: (2014) -
Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study
por: Sasaki, Tsuyoshi, et al.
Publicado: (2014)